5,6-Dihydroabiraterone
Product Specifications
UNSPSC Description
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer)[1][2].
Target Antigen
Drug Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/5-6-dihydroabiraterone.html
Solubility
10 mM in DMSO
Smiles
C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC2
Molecular Weight
351.52
References & Citations
[1]Alyamani M, et al. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol. 2017 Sep;172:231-239.|[2]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-137193/5-6-Dihydroabiraterone-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-137193/
Clinical Information
No Development Reported
CAS Number
219843-75-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6287808-01 0.1 mL
COMMD9, CT (COMMD9, COMM domain-containing protein 9) (MaxLight 550)
Ask
View Details 
MBS6287808-02 5x 0.1 mL
COMMD9, CT (COMMD9, COMM domain-containing protein 9) (MaxLight 550)
Ask
View Details